
doi: 10.1038/nrd.2016.258
pmid: 27895335
Clinical Trials, Phase II as Topic, Drug Design, PCSK9 Inhibitors, Humans, Hyperlipidemias, Proprotein Convertase 9, Hypolipidemic Agents
Clinical Trials, Phase II as Topic, Drug Design, PCSK9 Inhibitors, Humans, Hyperlipidemias, Proprotein Convertase 9, Hypolipidemic Agents
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
